Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chubb
Harvard Business School
McKesson
Teva
Fuji
Healthtrust
Express Scripts
Medtronic

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMIQUIMOD

« Back to Dashboard

Clinical Trials for Imiquimod

Trial ID Title Status Sponsor Phase Summary
NCT00031759 Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical cancer. PURPOSE: Randomized phase II trial to study the effectiveness of applying topical imiquimod before abnormal cervical cells are removed in preventing cervical cancer in patients who have recurrent or persistent cervical neoplasia.
NCT00031759 Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia Completed Alliance for Clinical Trials in Oncology Phase 2 RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical cancer. PURPOSE: Randomized phase II trial to study the effectiveness of applying topical imiquimod before abnormal cervical cells are removed in preventing cervical cancer in patients who have recurrent or persistent cervical neoplasia.
NCT00066872 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed Queen's Medical Centre Phase 3 RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer. PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.
NCT00079300 Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer Completed National Naval Medical Center Phase 1 RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This randomized phase I trial is studying how well imiquimod cream works in treating patients with basal cell skin cancer.
NCT00110682 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed 3M Phase 4 Study Aims: - To compare the long-term efficacy and safety of imiquimod versus vehicle used as an adjunct to cryotherapy. - To assess and compare the recurrence rate and time to recurrence of the 2 different treatment groups. Hypothesis: The imiquimod arm will produce a more prolonged clearing of Actinic Keratoses (AK) compared to the vehicle arm.
NCT00110682 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed Derm Research @ 888 Inc. Phase 4 Study Aims: - To compare the long-term efficacy and safety of imiquimod versus vehicle used as an adjunct to cryotherapy. - To assess and compare the recurrence rate and time to recurrence of the 2 different treatment groups. Hypothesis: The imiquimod arm will produce a more prolonged clearing of Actinic Keratoses (AK) compared to the vehicle arm.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Imiquimod

Condition Name

Condition Name for Imiquimod
Intervention Trials
Actinic Keratosis 19
Actinic Keratoses 8
Cervical Intraepithelial Neoplasia 7
Lentigo Maligna 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Imiquimod
Intervention Trials
Keratosis 32
Keratosis, Actinic 32
Carcinoma, Basal Cell 14
Carcinoma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Imiquimod

Trials by Country

Trials by Country for Imiquimod
Location Trials
United States 278
United Kingdom 19
Canada 10
Austria 10
Germany 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Imiquimod
Location Trials
New York 19
Florida 19
California 18
Illinois 15
Texas 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Imiquimod

Clinical Trial Phase

Clinical Trial Phase for Imiquimod
Clinical Trial Phase Trials
Phase 4 21
Phase 3 33
Phase 2/Phase 3 5
[disabled in preview] 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Imiquimod
Clinical Trial Phase Trials
Completed 68
Recruiting 23
Not yet recruiting 11
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Imiquimod

Sponsor Name

Sponsor Name for Imiquimod
Sponsor Trials
Graceway Pharmaceuticals, LLC 15
National Cancer Institute (NCI) 15
MEDA Pharma GmbH & Co. KG 11
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Imiquimod
Sponsor Trials
Other 130
Industry 59
NIH 16
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Cerilliant
Federal Trade Commission
Teva
Merck
Accenture
Chinese Patent Office
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.